Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Capital Expenditures (2020 - 2025)

GeneDx Holdings has reported Capital Expenditures over the past 6 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $4.3 million for Q4 2025, up 266.42% from a year ago — trailing twelve months through Dec 2025 was $19.0 million (changed N/A YoY), and the annual figure for FY2025 was $19.0 million, changed.
  • Capital Expenditures for Q4 2025 was $4.3 million at GeneDx Holdings, down from $6.2 million in the prior quarter.
  • Over the last five years, Capital Expenditures for WGSWW hit a ceiling of $9.2 million in Q4 2021 and a floor of -$5.0 million in Q4 2022.
  • Median Capital Expenditures over the past 5 years was $1.3 million (2021), compared with a mean of $1.4 million.
  • Biggest five-year swings in Capital Expenditures: crashed 389.85% in 2023 and later surged 16925.0% in 2025.
  • GeneDx Holdings' Capital Expenditures stood at $9.2 million in 2021, then tumbled by 154.2% to -$5.0 million in 2022, then skyrocketed by 78.24% to -$1.1 million in 2023, then crashed by 140.52% to -$2.6 million in 2024, then skyrocketed by 266.42% to $4.3 million in 2025.
  • The last three reported values for Capital Expenditures were $4.3 million (Q4 2025), $6.2 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.